Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase
administered to hemodialysis patients.
A single dose of pegloticase will be administered intravenously to male or female
hemodialysis patients (N = 12) starting 3 hour prior to dialysis.
The study consists of a Screening Period, a Treatment Period, and Follow up Period.